Nick Leschly Sells 25,667 Shares of bluebird bio, Inc. (BLUE) Stock
bluebird bio, Inc. (NASDAQ:BLUE) insider Nick Leschly sold 25,667 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $115.18, for a total transaction of $2,956,325.06. Following the sale, the insider now directly owns 339,368 shares of the company’s stock, valued at approximately $39,088,406.24. The sale was disclosed in a filing with the SEC, which is available at this link.
Nick Leschly also recently made the following trade(s):
- On Tuesday, June 27th, Nick Leschly sold 25,000 shares of bluebird bio stock. The shares were sold at an average price of $108.05, for a total transaction of $2,701,250.00.
bluebird bio, Inc. (BLUE) opened at 130.85 on Friday. The stock has a 50 day moving average of $98.27 and a 200 day moving average of $93.20. The firm’s market capitalization is $5.97 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $133.10.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. During the same quarter in the previous year, the firm posted ($1.59) earnings per share. bluebird bio’s revenue for the quarter was up 977.4% compared to the same quarter last year. Analysts forecast that bluebird bio, Inc. will post ($6.82) earnings per share for the current year.
Several analysts recently issued reports on BLUE shares. Cantor Fitzgerald set a $37.00 price objective on shares of bluebird bio and gave the company a “sell” rating in a research note on Monday, June 5th. BTIG Research cut shares of bluebird bio from a “buy” rating to a “neutral” rating and increased their price target for the company from $37.05 to $108.25 in a research note on Friday, June 30th. Zacks Investment Research raised shares of bluebird bio from a “sell” rating to a “hold” rating in a research note on Monday, May 8th. Jefferies Group LLC reissued a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Finally, Maxim Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $102.68.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantitative Investment Management LLC acquired a new position in shares of bluebird bio during the first quarter worth $736,000. Parametric Portfolio Associates LLC boosted its position in shares of bluebird bio by 11.5% in the first quarter. Parametric Portfolio Associates LLC now owns 22,743 shares of the biotechnology company’s stock worth $2,067,000 after buying an additional 2,338 shares during the period. Karp Capital Management Corp acquired a new position in shares of bluebird bio during the first quarter worth $410,000. Smith Asset Management Group LP acquired a new position in shares of bluebird bio during the first quarter worth $311,000. Finally, Pictet Asset Management Ltd. boosted its position in shares of bluebird bio by 26.2% in the first quarter. Pictet Asset Management Ltd. now owns 182,841 shares of the biotechnology company’s stock worth $16,620,000 after buying an additional 37,925 shares during the period.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.